Overview: Everolimus TestIntroduction: The Everolimus Test measures everolimus levels to monitor transplant or cancer treatment, preventing organ rejection or tumor growth. Following 2023 AST guidelines, it uses an immunoassay for high sensitivity, aiding in drug monitoring. This test is critical for guiding dosing, preventing toxicity, and improving outcomes in toxicology for patients on everolimus therapy.
Other Names: Everolimus Assay, Immunosuppressant Drug Test.
FDA Status: Laboratory-developed test (LDT), meeting toxicology standards for diagnostic accuracy.
Historical Milestone: Everolimus testing began in the 2000s with transplant and oncology research. Immunoassays emerged in the 2010s, improving accuracy for drug monitoring.
Purpose: Monitors everolimus levels, guides dosing, and prevents toxicity in patients with transplant rejection or cancer.
Test Parameters: 1. Everolimus
Pretest Condition: Fasting for 10-12 hours required to stabilize drug levels. Collect whole blood before the next dose. Report symptoms like organ dysfunction or tumor growth, and list medications.
Specimen: 2-5 mL whole blood (EDTA). Transport in a biohazard bag within 8 hours.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document transplant history, cancer, or symptoms like organ dysfunction. Include current medications, especially immunosuppressants or chemotherapeutics.
Consent: Written consent required, detailing the tests purpose, implications for dosing, and potential need for therapy adjustments.
Procedural Considerations: Uses an immunoassay to measure everolimus levels. Results are available in 3-5 days, enabling clinical decisions.
Factors Affecting Result Accuracy: Non-fasting or drug interactions can affect results. Hemolysis may degrade samples.
Clinical Significance: Abnormal everolimus levels indicate need for dose adjustment to prevent toxicity or inefficacy. Therapeutic levels support ongoing monitoring.
Specialist Consultation: Consult a transplant specialist or oncologist for result interpretation.
Additional Supporting Tests: Kidney/liver function tests, biopsy, or imaging to monitor transplant or cancer status.
Test Limitations: Results may vary with drug interactions. Clinical correlation is required.
References: AST Transplant Guidelines, 2023; American Journal of Transplantation, Pascual J, 2022.
